# SARS-CoV-2 Variant Testing

> **NIH NIH R01** · MASSACHUSETTS GENERAL HOSPITAL · 2021 · $348,242

## Abstract

Abstract
 The robust protection conferred by emerging EUA approved SARS-CoV-2 vaccines represents a critical milestone in COVID-19 vaccine development. However, the emergence of variants has inspired renewed concern related to the protective efficacy of currently approved vaccines, which lose neutralizing potency against some variants. However, emerging data suggest that antibody functions, beyond neutralization, that emerge early after vaccination and that persist even with a loss of neutralization, may contribute to protection from disease. Thus, here we aim to profile the evolution of the breadth of the VOC-specific Fc-effector functions of vaccine induced antibodies across vaccine platforms. Specifically, we aim to profile the subclass, isotypes, Fc-receptor binding, complement depositing function, cellular cytotoxicity, opsinophagocytic activity, degranulation, and mucus trapping days after vaccination compared to convalescent individuals. These data will be compared to breakthrough infection cases from Novavax (& Medicago) and J&J.

## Key facts

- **NIH application ID:** 10446500
- **Project number:** 3R01AI146785-02S1
- **Recipient organization:** MASSACHUSETTS GENERAL HOSPITAL
- **Principal Investigator:** Galit Alter
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $348,242
- **Award type:** 3
- **Project period:** 2021-08-17 → 2022-09-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10446500

## Citation

> US National Institutes of Health, RePORTER application 10446500, SARS-CoV-2 Variant Testing (3R01AI146785-02S1). Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/grant/nih/10446500. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*